Skip to content
10-Q

Quarterly Report

KERYX BIOPHARMACEUTICALS INC

0001114220-18-000104

← back to feed
Filed
Nov 8, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2018 · Oct 31, 2018 102.38M sh
Capex Q3 2018 · Sep 30, 2018 $52K
Capex Q3 2018 · Sep 30, 2017 $1.18M
Operating Cash Flow Q3 2018 · Sep 30, 2018 −$78.18M
Operating Cash Flow Q3 2018 · Sep 30, 2017 −$73.31M
Cash And Equivalents Q3 2018 · Sep 30, 2018 $41.15M
Cash And Equivalents Q3 2018 · Dec 31, 2017 $93.53M
Cash And Equivalents Q3 2018 · Sep 30, 2017 $114M
Cash And Equivalents Q3 2018 · Dec 31, 2016 $111.81M
Stockholders Equity Q3 2018 · Sep 30, 2018 −$54.22M
Stockholders Equity Q3 2018 · Dec 31, 2017 −$14.1M
Current Liabilities Q3 2018 · Sep 30, 2018 $57.1M
Current Liabilities Q3 2018 · Dec 31, 2017 $45.42M
Total Liabilities Q3 2018 · Sep 30, 2018 $206M
Total Liabilities Q3 2018 · Dec 31, 2017 $172.97M
Current Assets Q3 2018 · Sep 30, 2018 $126.41M
Current Assets Q3 2018 · Dec 31, 2017 $141.57M
Total Assets Q3 2018 · Sep 30, 2018 $151.78M
Total Assets Q3 2018 · Dec 31, 2017 $158.87M
Sga Expense Q3 2018 · Sep 30, 2018 $26.45M
Sga Expense Q3 2018 · Sep 30, 2018 $81M
Sga Expense Q3 2018 · Sep 30, 2017 $22.75M
Sga Expense Q3 2018 · Sep 30, 2017 $70.84M
Rd Expense Q3 2018 · Sep 30, 2018 $7.9M
Rd Expense Q3 2018 · Sep 30, 2018 $25.06M
Rd Expense Q3 2018 · Sep 30, 2017 $9.28M
Rd Expense Q3 2018 · Sep 30, 2017 $25.05M
Net Income Q3 2018 · Sep 30, 2018 −$17M
Net Income Q3 2018 · Sep 30, 2018 −$60.41M
Net Income Q3 2018 · Sep 30, 2017 −$23.5M
Net Income Q3 2018 · Sep 30, 2017 −$133.01M
Operating Income Q3 2018 · Sep 30, 2018 −$14.69M
Operating Income Q3 2018 · Sep 30, 2018 −$57.59M
Operating Income Q3 2018 · Sep 30, 2017 −$23.72M
Operating Income Q3 2018 · Sep 30, 2017 −$70.68M
Revenue Q3 2018 · Sep 30, 2018 $28.04M
Revenue Q3 2018 · Sep 30, 2018 $75.54M
Revenue Q3 2018 · Sep 30, 2017 $15M
Revenue Q3 2018 · Sep 30, 2017 $41.96M